cea12220-sup-0001-FigS1-S5-TableS1.docWord document1174KData S1. Methods.
cea12220-sup-0002-FigS1.tifimage/tif59KFigure S1. Study patient flowchart.
cea12220-sup-0003-FigS2.tifimage/tif1840KFigure S2. Late allergen response AUC FEV1 at Week 13 for each subject plotted by site.
cea12220-sup-0004-FigS3.tifimage/tif66KFigure S3. Serum concentration–time profile of lebrikizumab.
cea12220-sup-0004-FigS4.tifimage/tif156KFigure S4. Serum levels of IgE, CCL13, and CCL17 and relationship between predose levels of serum IgE, CCL13, and CCL17 with magnitude of effect.
cea12220-sup-0005-FigS5.tiffTIFF image323KFigure S5. Serum levels of periostin, CEA, and YKL-40.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.